# NutriBand Inc.: overview

NTRB · Nasdaq · CIK 1676047 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/ntrb.md) · [Financials](/companies/ntrb/financials.md) · [Filings](/companies/ntrb/filings.md) · [Insiders](/companies/ntrb/insiders.md)

Latest reported revenue: [$437.5k](/filings/0001213900-26-097701.md) for Q2 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 4, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-097701).

## Last eight quarters

| Line item | Unit | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [646](/filings/0001213900-25-120204.md) | [642 d](/filings/0001213900-26-049399.md) | [667](/filings/0001213900-26-067840.md) | [622](/filings/0001213900-26-097701.md) | [346](/filings/0001213900-25-120204.md) | [401 d](/filings/0001213900-26-049399.md) | [433](/filings/0001213900-26-067840.md) | [438](/filings/0001213900-26-097701.md) |
| Gross margin | % | [29.6%](/filings/0001213900-25-120204.md) | [44.5% d](/filings/0001213900-26-049399.md) | [37.8%](/filings/0001213900-25-049455.md) | [25.2%](/filings/0001213900-25-086270.md) | [19.8%](/filings/0001213900-25-120204.md) | [22.2% d](/filings/0001213900-26-049399.md) | not reported | not reported |
| Operating margin | % | [(220.9%)](/filings/0001213900-25-120204.md) | [(865.3%) d](/filings/0001213900-26-049399.md) | [(211.8%)](/filings/0001213900-26-067840.md) | [(321.8%)](/filings/0001213900-26-097701.md) | [(1121.3%)](/filings/0001213900-25-120204.md) | [(254.8%) d](/filings/0001213900-26-049399.md) | [(289.4%)](/filings/0001213900-26-067840.md) | [(203.6%)](/filings/0001213900-26-097701.md) |
| Net margin | % | [(211.0%)](/filings/0001213900-25-120204.md) | [(858.8%) d](/filings/0001213900-26-049399.md) | [(208.1%)](/filings/0001213900-26-067840.md) | [(321.4%)](/filings/0001213900-26-097701.md) | [(1119.0%)](/filings/0001213900-25-120204.md) | [(241.6%) d](/filings/0001213900-26-049399.md) | [(286.6%)](/filings/0001213900-26-067840.md) | [(201.3%)](/filings/0001213900-26-097701.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001213900-25-120204.md) | not reported | [(0.12)](/filings/0001213900-26-067840.md) | [(2.12)](/filings/0001213900-26-097701.md) | [(0.32)](/filings/0001213900-25-120204.md) | not reported | [(0.10)](/filings/0001213900-26-067840.md) | [(0.07)](/filings/0001213900-26-097701.md) |
| Free cash flow | $k | [(1,057) d](/filings/0001213900-25-120204.md) | [(1,239) d](/filings/0001213900-26-049399.md) | [(1,342)](/filings/0001213900-26-067840.md) | [(1,313) d](/filings/0001213900-26-097701.md) | [(1,752) d](/filings/0001213900-25-120204.md) | [(732) d](/filings/0001213900-26-049399.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-01-31) | FY2023 (2023-01-31) | FY2024 (2024-01-31) | FY2025 (2025-01-31) | FY2026 (2026-01-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,422](/filings/0001213900-23-032682.md) | [2,080](/filings/0001213900-24-037996.md) | [2,085](/filings/0001213900-25-036201.md) | [2,140](/filings/0001213900-26-049399.md) | [2,037](/filings/0001213900-26-049399.md) |
| Gross margin | % | [39.0%](/filings/0001213900-23-032682.md) | [36.1%](/filings/0001213900-23-032682.md) | [41.3%](/filings/0001213900-25-036201.md) | [34.7%](/filings/0001213900-26-049399.md) | [27.8%](/filings/0001213900-26-049399.md) |
| Operating margin | % | [(429.7%)](/filings/0001213900-23-032682.md) | [(215.2%)](/filings/0001213900-24-037996.md) | [(233.6%)](/filings/0001213900-25-036201.md) | [(480.7%)](/filings/0001213900-26-049399.md) | [(408.4%)](/filings/0001213900-26-049399.md) |
| Net margin | % | [(434.3%)](/filings/0001213900-23-032682.md) | [(215.6%)](/filings/0001213900-24-037996.md) | [(263.0%)](/filings/0001213900-25-036201.md) | [(489.9%)](/filings/0001213900-26-049399.md) | [(404.1%)](/filings/0001213900-26-049399.md) |
| Diluted EPS | $ per share | [(0.80)](/filings/0001213900-23-032682.md) | [(0.53)](/filings/0001213900-24-037996.md) | [(0.69)](/filings/0001213900-25-036201.md) | [(0.99)](/filings/0001213900-26-049399.md) | [(2.58)](/filings/0001213900-26-049399.md) |
| Free cash flow | $k | [(2,891)](/filings/0001213900-23-032682.md) | [(3,067)](/filings/0001213900-24-037996.md) | [(3,579)](/filings/0001213900-25-036201.md) | [(4,719)](/filings/0001213900-26-049399.md) | [(5,140)](/filings/0001213900-26-049399.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ntrb/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $558.0k | 174,927 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $199.4k | 62,494 |  | Reduced −7,559 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $80.1k | 25,111 |  | Unchanged |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $79.6k | 24,966 |  | Unchanged |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $60.6k | 18,996 |  | New +18,996 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $36.9k | 11,570 |  | Reduced −2,375 |
| [Haven Private, LLC](/funds/2053665.md) | 2026-06-30 | $36.3k | 11,366 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $34.0k | 10,662 |  | Added +1,121 |
| [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $11.8k | 3,684 |  | Reduced −1,167 |
| [Vanguard Global Advisers, LLC](/funds/1811242.md) | 2026-06-30 | $8.6k | 2,700 |  | Unchanged |

## Recent filings

[All 261 filings](/companies/ntrb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 17:27 ET | [8-K](/filings/0001213900-26-102721.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-102721 |
| 2026-09-15 | 15:48 ET | [SCHEDULE 13D/A](/filings/0001213900-26-100103.md) | Ownership report, active investor, amended | 0001213900-26-100103 |
| 2026-09-04 | 16:31 ET | [10-Q](/filings/0001213900-26-097701.md) | Quarterly report, period 2026-07-31 | 0001213900-26-097701 |
| 2026-06-22 | 08:02 ET | [8-K](/filings/0001213900-26-070378.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-070378 |
| 2026-06-11 | 16:20 ET | [10-Q](/filings/0001213900-26-067840.md) | Quarterly report, period 2026-04-30 | 0001213900-26-067840 |
| 2026-05-18 | 16:44 ET | [10-K/A](/filings/0001213900-26-058507.md) | Annual report, amended, period 2026-01-31 | 0001213900-26-058507 |
| 2026-04-29 | 17:13 ET | [10-K](/filings/0001213900-26-049399.md) | Annual report, period 2026-01-31 | 0001213900-26-049399 |
| 2026-04-07 | 15:43 ET | [8-K](/filings/0001213900-26-041006.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-041006 |
| 2026-02-13 | 16:58 ET | [8-K](/filings/0001213900-26-016550.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-016550 |
| 2026-02-03 | 13:44 ET | [8-K](/filings/0001213900-26-011304.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-011304 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 31, 2026](/filings/0001213900-26-049399.md), filed Apr 29, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1676047
- Tickers: NTRB, NTRBW
- Exchange: Nasdaq
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: NV
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.